| 1. | BUYtheWeak | |
| 2. | johnhoar | |
| 3. | MamisTrist | |
| 4. | nlanas2sk051p |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | johnhoar 04/03/2018 EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma |
| 2. | johnhoar 03/10/2018 Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate |
| 3. | johnhoar 01/30/2018 Great news - Company granted orphan drug designation by the FDA for its compound for the treatment of follicular lymphoma |
| 4. | nlanas2sk051p 02/08/2018 Seeing EPS beats reported by $0.63 and by $0.70. Beats on revenues. |
| 5. | BUYtheWeak 09/12/2017 @MamisTrist Yup, looking like it if you haven't already |
| 6. | MamisTrist 09/12/2017 Time to buy? |
| 7. | MamisTrist 03/02/2018 FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma |
| 8. | BUYtheWeak 01/24/2018 More good news |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Regeneron Pharmaceuticals, Inc.
- REGN
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.